

Ref. No	Title of guidance	NICE Publication Date	Applicable to WMUH?	Current Implementation Status at present
TA001	Wisdom teeth - removal	Mar-00	No	Guidance is not applicable to WMUH
TA002	Hip disease - replacement prostheses (replaced by TA304)	Apr-00	Superseded Guidance	Superseded Guidance
TA003	Ovarian cancer - taxanes (replaced by TA55)	May-00	Superseded Guidance	Superseded Guidance
TA004	Ischaemic heart disease - coronary artery stents (replaced by TA71)	May-00	Superseded Guidance	Superseded Guidance
TA005	Cervical cancer - liquid based cytology (replaced by TA69)	Jun-00	Superseded Guidance	Superseded Guidance
TA006	Breast cancer - taxanes (replaced by TA30)	Jun-00	Superseded Guidance	Superseded Guidance
TA007	Dyspepsia - proton pump inhibitors (replaced by CG17)	Jul-00	Superseded Guidance	Superseded Guidance
TA008	Hearing disability - hearing aids (withdrawn)	Jul-00	Terminated Appraisal	Terminated Appraisal
TA009	Diabetes (type 2) - rosiglitazone (replaced by TA63)	Aug-00	Superseded Guidance	Superseded Guidance
TA010	Asthma (children under 5) - inhaler devices	Aug-00	Yes	Fully implemented
TA011	Arrhythmias - implantable cardioverter defibrillators (ICDs) (replaced by TA95)	Sep-00	Superseded Guidance	Superseded Guidance
TA012	Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (replaced by TA47)	Sep-00	Superseded Guidance	Superseded Guidance
TA013	Attention deficit hyperactivity disorder (ADHD) - methylphenidate (replaced by TA98)	Oct-00	Superseded Guidance	Superseded Guidance
TA014	Hepatitis C - alpha interferon and ribavirin (replaced by TA75)	Oct-00	Superseded Guidance	Superseded Guidance
TA015	Flu - zanamivir (replaced by TA58)	Nov-00	Superseded Guidance	Superseded Guidance
TA016	Knee joints (defective) - autologous cartilage transplantation (replaced by TA89)	Dec-00	Superseded Guidance	Superseded Guidance
TA017	Colorectal cancer - laparoscopic surgery (replaced by TA105)	Dec-00	Superseded Guidance	Superseded Guidance
TA018	Hernia (inguinal) - laparoscopic surgery (replaced by TA83)	Jan-01	Superseded Guidance	Superseded Guidance
TA019	Alzheimer's disease - donepezil, rivastigmine and galantamine (replaced by TA111)	Jan-01	Superseded Guidance	Superseded Guidance
TA020	Motor neurone disease - riluzole	Jan-01	Yes	Fully implemented
TA021	Diabetes (type 2) - pioglitazone (replaced by TA63)	Mar-01	Superseded Guidance	Superseded Guidance
TA022	Obesity - orlistat (replaced by CG43)	Mar-01	Superseded Guidance	Superseded Guidance
TA024	Wound care - debriding agents (replaced by CG74)	Apr-01	Superseded Guidance	Superseded Guidance
TA026	Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine (replaced by CG24)	Jun-01	Superseded Guidance	Superseded Guidance
TA027	Osteoarthritis and rheumatoid arthritis - cox II inhibitors (replaced by CG59 and CG79)	Jul-01	Superseded Guidance	Superseded Guidance
TA028	Ovarian cancer - topotecan (replaced by TA91)	Jul-01	Superseded Guidance	Superseded Guidance
TA029	Leukaemia (lymphocytic) - fludarabine	Sep-01	Yes	Fully implemented
TA030	Breast cancer - taxanes (review)(replaced by CG81)	Sep-01	Superseded Guidance	Superseded Guidance
TA031	Obesity - sibutramine (replaced by CG43)	Oct-01	Superseded Guidance	Superseded Guidance
TA032	Multiple sclerosis - beta interferon and glatiramer acetate	Jan-02	No	Guidance is not applicable to WMUH
TA033	Colorectal cancer (advanced) - irinotecan, oxaliplatin & raltitrexed (replaced by TA93)	Mar-02	Superseded Guidance	Superseded Guidance
TA034	Breast cancer - trastuzumab	Mar-02	Yes	Fully implemented
TA035	Arthritis (juvenile idiopathic) - etanercept (replaced by TA373)	Mar-02	Superseded Guidance	Superseded Guidance
TA036	Rheumatoid arthritis - etanercept and infliximab (replaced by TA130 and TA195)	Mar-02	Superseded Guidance	Superseded Guidance
TA037	Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137)	Mar-02	Superseded Guidance	Superseded Guidance
TA038	Asthma (older children) - inhaler devices	Mar-02	Yes	Fully implemented
TA039	Smoking cessation - bupropion and nicotine replacement therapy (replaced by PH10)	Mar-02	Superseded Guidance	Superseded Guidance
TA040	Crohn's disease - infliximab (replaced by TA187)	Apr-02	Superseded Guidance	Superseded Guidance
TA041	Pregnancy - routine anti-D prophylaxis for RhD-negative women (replaced by TA156)	May-02	Superseded Guidance	Superseded Guidance
TA042	Growth hormone deficiency (children) - human growth hormone (replaced by TA188)	May-02	Superseded Guidance	Superseded Guidance
TA043	Schizophrenia - atypical antipsychotics (replaced by CG82)	Jun-02	Superseded Guidance	Superseded Guidance
TA044	Hip disease - metal on metal hip resurfacing (replacing TA304)	Jun-02	Superseded Guidance	Superseded Guidance
TA045	Ovarian cancer (advanced) - pegylated liposomal doxorubicin hydrochloride (replaced by TA91)	Jul-02	Superseded Guidance	Superseded Guidance
TA046	Obesity (morbid) - surgery (replaced by CG43)	Jul-02	Superseded Guidance	Superseded Guidance
TA047	Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (replaced by CG94)	Sep-02	Superseded Guidance	Superseded Guidance
TA048	Renal failure - home versus hospital haemodialysis	Sep-02	No	Guidance is not applicable to WMUH
TA049	Central venous catheters - ultrasound locating devices	Sep-02	No	Guidance is not applicable to WMUH
TA050	Leukaemia (chronic myeloid) - imatinib (replaced by TA70)	Oct-02	Superseded Guidance	Superseded Guidance
TA051	Depression and anxiety - computerised cognitive behaviour therapy (CCBT) (replaced by TA97)	Oct-02	Superseded Guidance	Superseded Guidance
TA052	Myocardial infarction - thrombolysis	Oct-02	No	Guidance is not applicable to WMUH
TA053	Diabetes (types 1 and 2) - long acting insulin analogues (replaced by NG17)	Dec-02	Superseded Guidance	Superseded Guidance
TA054	Breast cancer - vinorelbine (replaced by CG81)	Dec-02	Superseded Guidance	Superseded Guidance
TA055	Ovarian cancer - paclitaxel (partially updated by TA91)	Jan-03	No	Guidance is not applicable to WMUH
TA056	Stress incontinence - tension-free vaginal tape (replaced by CG40)	Feb-03	Superseded Guidance	Superseded Guidance
TA057	Diabetes (type 1) - insulin pump therapy (replaced by TA151)	Feb-03	Superseded Guidance	Superseded Guidance
TA058	Flu treatment - zanamivir (review), amantadine and oseltamivir (replaced by TA168)	Feb-03	Superseded Guidance	Superseded Guidance
TA059	Electroconvulsive therapy (ECT)	Apr-03	No	Guidance is not applicable to WMUH
TA060	Diabetes (types 1 and 2) - patient education models (replaced by CG66)	Apr-03	Superseded Guidance	Superseded Guidance
TA061	Colorectal cancer - capecitabine and tegafur uracil	May-03	Yes	Fully implemented
TA062	Breast cancer - capecitabine (replaced by CG81)	May-03	Superseded Guidance	Superseded Guidance
TA063	Diabetes (type 2) - glitazones (replaced by CG66)	Aug-03	Superseded Guidance	Superseded Guidance
TA064	Growth hormone deficiency (adults) - human growth hormone	Aug-03	Yes	Fully implemented
TA065	Non-Hodgkin's lymphoma - rituximab	Sep-03	Yes	Fully implemented
TA066	Bipolar disorder - new drugs (replaced by CG38)	Sep-03	Superseded Guidance	Superseded Guidance
TA067	Flu prevention - amantadine and oseltamivir (replaced by TA158)	Sep-03	Superseded Guidance	Superseded Guidance
TA068	Macular degeneration (age-related) - photodynamic therapy	Sep-03	No	Guidance is not applicable to WMUH
TA069	Cervical cancer - cervical screening	Oct-03	No	Guidance is not applicable to WMUH
TA070	Leukaemia (chronic myeloid) - imatinib (partially updated by TA241 and TA251)	Oct-03	Yes	Fully implemented
TA071	Ischaemic heart disease - coronary artery stents (Sections 1.2-1.4 replaced by TA152)	Oct-03	No	Guidance is not applicable to WMUH
TA072	Rheumatoid arthritis - anakinra (replaced by CG79)	Nov-03	Superseded Guidance	Superseded Guidance
TA073	Angina and myocardial infarction - myocardial perfusion scintigraphy (Partly updated by CG95 and CG126)	Nov-03	No	Guidance is not applicable to WMUH
TA074	Trauma - fluid replacement therapy	Jan-04	No	Guidance is not applicable to WMUH
TA075	Hepatitis C - pegylated interferons, ribavirin and alfa interferon (partially updated by TA200 and TA300)	Jan-04	No	Guidance is not applicable to WMUH
TA076	Epilepsy (adults) - newer drugs (replaced by CG137)	Mar-04	Superseded Guidance	Superseded Guidance
TA077	Insomnia - newer hypnotic drugs	Apr-04	Yes	Fully implemented
TA078	Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation	Apr-04	No	Guidance is not applicable to WMUH
TA079	Epilepsy (children) - newer drugs (replaced by CG137)	Apr-04	Superseded Guidance	Superseded Guidance
TA080	Acute coronary syndromes - clopidogrel (replaced by CG94)	Jul-04	Superseded Guidance	Superseded Guidance
TA081	Atopic dermatitis (eczema) - topical steroids	Aug-04	Yes	Fully implemented
TA082	Atopic dermatitis (eczema) - pimecrolimus and tacrolimus	Aug-04	Yes	Fully implemented
TA083	Laparoscopic surgery for inguinal hernia repair (replaced by TA18)	Sep-04	Yes	Fully implemented
TA084	Sepsis (severe) - drotrecogin	Sep-04	Guidance withdrawn	Guidance withdrawn
TA085	Renal transplantation - immuno-suppressive regimens (adults)	Sep-04	No	Guidance is not applicable to WMUH
TA086	Gastro-intestinal stromal tumours (GIST) - imatinib (partially updated by TA209)	Oct-04	No	Guidance is not applicable to WMUH
TA087	Osteoporosis - secondary prevention (replaced by TA161)	Jan-05	Superseded Guidance	Superseded Guidance
TA088	Bradycardia - dual chamber pacemakers (partially updated by TA324)	Feb-05	No	Guidance is not applicable to WMUH
TA089	Cartilage injury - autologous chondrocyte implantation (ACI)	May-05	No	Guidance is not applicable to WMUH
TA090	Vascular disease - clopidogrel and dipyridamole (replaced by TA210)	May-05	Superseded Guidance	Superseded Guidance
TA091	Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (replaced by TA389)	May-05	No	Guidance is not applicable to WMUH
TA092	Tooth decay - HealOzone	Jul-05	No	Not recommended
TA093	Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (replaced by CG131)	Aug-05	Superseded Guidance	Superseded Guidance
TA094	Cardiovascular disease - statins (replaced by CG181)	Jan-06	Superseded Guidance	Superseded Guidance
TA095	Arrhythmia - implantable cardioverter defibrillators (ICDs) (replaced by TA314)	Jan-06	Superseded Guidance	Superseded Guidance

TA096	Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (partially updated by CG165)	Feb-06	No	Guidance is not applicable to WMUH
TA097	Depression and anxiety - computerised cognitive behavioural therapy (CCBT)	Feb-06	No	Guidance is not applicable to WMUH
TA098	Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine	Mar-06	No	Guidance is not applicable to WMUH
TA099	Renal transplantation - immunosuppressive regimens for children and adolescents	Apr-06	No	Guidance is not applicable to WMUH
TA100	Colon cancer (adjuvant) - capecitabine and oxaliplatin	Apr-06	No	Guidance is not applicable to WMUH
TA101	Prostate cancer (hormone-refractory) - docetaxel	Jun-06	No	Guidance is not applicable to WMUH
TA102	Conduct disorder in children - parent-training/education programmes (replaced by CG158)	Jul-06	Superseded Guidance	Superseded Guidance
TA103	Psoriasis - efalizumab and etanercept	Jul-06	No	Guidance is not applicable to WMUH
TA104	Psoriatic arthritis - etanercept and infliximab (replaced by TA199)	Jul-06	Superseded Guidance	Superseded Guidance
TA105	Colorectal cancer - laparoscopic surgery	Aug-06	Yes	Fully implemented
TA106	Hepatitis C - peginterferon alfa and ribavirin (Guidance extension of TA75)	Aug-06	No	Guidance is not applicable to WMUH
TA107	Breast cancer (early) - trastuzumab (replaced by CG80)	Aug-06	Superseded Guidance	Superseded Guidance
TA108	Breast cancer (early) - paclitaxel (replaced by CG80)	Sep-06	Superseded Guidance	Superseded Guidance
TA109	Breast cancer (early) - docetaxel (replaced by CG80)	Sep-06	Superseded Guidance	Superseded Guidance
TA110	Follicular lymphoma - rituximab (replaced by TA243)	Sep-06	Superseded Guidance	Superseded Guidance
TA111	Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine (replaced by TA217)	Sep-06	Superseded Guidance	Superseded Guidance
TA112	Breast cancer (early) - hormonal treatments	Nov-06	No	Guidance is not applicable to WMUH
TA113	Diabetes (type 1 and 2) - inhaled insulin	Dec-06	No	Production ceased
TA114	Drug misuse - methadone and buprenorphine	Jan-07	No	Guidance is not applicable to WMUH
TA115	Drug misuse - naltrexone	Jan-07	No	Guidance is not applicable to WMUH
TA116	Breast cancer - gemcitabine	Jan-07	No	Guidance is not applicable to WMUH
TA117	Hyperparathyroidism - cinacalcet	Jan-07	No	Guidance is not applicable to WMUH
TA118	Colorectal cancer (metastatic) - bevacizumab & cetuximab (partly updated by TA242)	Jan-07	No	Guidance is not applicable to WMUH
TA119	Leukaemia (lymphocytic) - fludarabine	Feb-07	Yes	Fully implemented
TA120	Heart failure - cardiac resynchronisation	May-07	No	Guidance is not applicable to WMUH
TA121	Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide	Jun-07	No	Guidance is not applicable to WMUH
TA122	Ischaemic stroke (acute) - alteplase	Jun-07	No	Guidance is not applicable to WMUH
TA123	Smoking cessation - varenicline	Jul-07	Yes	Fully implemented
TA124	Lung cancer (non-small-cell) - pemetrexed	Aug-07	No	Guidance is not applicable to WMUH
TA125	Psoriatic arthritis (moderate to severe) - adalimumab (replaced by TA199)	Aug-07	Superseded Guidance	Superseded Guidance
TA126	Rheumatoid arthritis (refractory) - rituximab (replaced by TA195)	Aug-07	Superseded Guidance	Superseded Guidance
TA127	Multiple sclerosis - natalizumab	Aug-07	No	Guidance is not applicable to WMUH
TA128	Stapled haemorrhoidopexy for the treatment of haemorrhoids	Sep-07	Yes	Fully implemented
TA129	Multiple myeloma - bortezomib	Oct-07	Yes	Fully implemented
TA130	Rheumatoid arthritis - adalimumab, etanercept and infliximab (replaced by NICE TA375)	Oct-07	Superseded Guidance	Superseded Guidance
TA131	Asthma (in children) - corticosteroids	Nov-07	Yes	Fully implemented
TA132	Hypercholesterolaemia - ezetimibe (replaced by TA385)	Nov-07	Superseded Guidance	Superseded Guidance
TA133	Asthma (uncontrolled) - omalizumab (replaced by TA278)	Nov-07	Superseded Guidance	Superseded Guidance
TA134	Psoriasis - infliximab	Jan-08	Yes	Fully implemented
TA135	Mesothelioma - pemetrexed disodium	Jan-08	No	Guidance is not applicable to WMUH
TA136	Structural neuroimaging in first-episode psychosis	Feb-08	No	Not recommended
TA137	Lymphoma (follicular non-Hodgkin's) - rituximab	Feb-08	Yes	Fully implemented
TA138	Asthma (in adults) - corticosteroids	Mar-08	Yes	Fully implemented
TA139	Continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea	Mar-08	Yes	Fully implemented
TA140	Ulcerative colitis (subacute manifestations) - infliximab (replaced by TA329)	Apr-08	Superseded Guidance	Superseded Guidance
TA141	Rheumatoid arthritis (refractory) - abatacept (replaced by TA195)	Apr-08	Superseded Guidance	Superseded Guidance
TA142	Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (replaced by TA323)	May-08	Superseded Guidance	Superseded Guidance
TA143	Ankylosing spondylitis - adalimumab, etanercept and infliximab (replaced by TA383)	May-08	Superseded Guidance	Superseded Guidance
TA144	Obesity - rimonabant	Jun-08	Terminated Appraisal	Terminated Appraisal
TA145	Head and neck cancer - cetuximab	Jun-08	No	Guidance is not applicable to WMUH
TA146	Psoriasis - adalimumab	Jun-08	Yes	Fully implemented
TA147	Breast cancer (advanced & metastatic) - bevacizumab (terminated appraisal)	Jun-08	Terminated Appraisal	Terminated Appraisal
TA148	Lung cancer (non-small-cell) - bevacizumab (terminated appraisal)	Jun-08	Terminated Appraisal	Terminated Appraisal
TA149	Glioma (recurrent) - carmustine implants (terminated appraisal)	Jun-08	Terminated Appraisal	Terminated Appraisal
TA150	Colorectal cancer (metastatic) - cetuximab (terminated appraisal)	Jun-08	Terminated Appraisal	Terminated Appraisal
TA151	Continuous Subcutaneous insulin infusion for the treatment of diabetes mellitus	Jul-08	Yes	Fully implemented
TA152	Coronary artery disease - drug-eluting stents	Jul-08	No	Guidance is not applicable to WMUH
TA153	Hepatitis B - entecavir	Aug-08	No	Not recommended
TA154	Hepatitis B - telbivudine	Aug-08	No	Guidance is not applicable to WMUH
TA155	Macular degeneration (age-related) - ranibizumab and pegaptanib	Aug-08	No	Guidance is not applicable to WMUH
TA156	Pregnancy (rhesus negative women) - routine anti-D (review)	Aug-08	Yes	Fully implemented
TA157	Venous thromboembolism - dabigatran	Sep-08	Yes	Fully implemented
TA158	Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir	Sep-08	Yes	Fully implemented
TA159	Pain (chronic neuropathic or ischaemic) - spinal cord stimulation	Oct-08	No	Guidance is not applicable to WMUH
TA160	Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women	Oct-08	Yes	Fully implemented
TA161	Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women	Oct-08	Yes	Fully implemented
TA162	Lung cancer (non-small-cell) - erlotinib (replaced by TA374)	Nov-08	Superseded Guidance	Superseded Guidance
TA163	Ulcerative colitis (acute exacerbations) - infliximab	Dec-08	Yes	Fully implemented
TA164	Hyperuricaemia - febuxostat	Dec-08	No	Guidance is not applicable to WMUH
TA165	Organ preservation (renal) - machine perfusion and static storage	Nov-08	No	Guidance is not applicable to WMUH
TA166	Hearing impairment - cochlear implants	Jan-09	No	Guidance is not applicable to WMUH
TA167	Abdominal aortic aneurysm - endovascular stent-grafts	Feb-09	No	Guidance is not applicable to WMUH
TA168	Influenza - zanamivir, amantadine and oseltamivir (review)	Feb-09	Yes	Fully implemented
TA169	Renal cell carcinoma - sunitinib	Mar-09	No	Guidance is not applicable to WMUH
TA170	Venous thromboembolism - rivaroxaban	Apr-09	Yes	Fully implemented
TA171	Multiple myeloma - lenalidomide	Jun-09	Yes	Fully implemented
TA172	Head and neck cancer (squamous cell carcinoma) - cetuximab	Jun-09	No	Not recommended
TA173	Hepatitis B - tenofovir disoproxil fumarate	Jul-09	No	Guidance is not applicable to WMUH
TA174	Leukaemia (chronic lymphocytic, first line) - rituximab	Jul-09	Yes	Fully implemented
TA175	Lung cancer (non-small-cell, second line) - gefitinib (replaced by TA374)	Jul-09	Superseded Guidance	Superseded Guidance
TA176	Colorectal cancer (first line) - cetuximab	Aug-09	No	Guidance is not applicable to WMUH
TA177	Eczema (chronic) - alitretinoin	Aug-09	Yes	Fully implemented
TA178	Renal cell carcinoma	Aug-09	No	Guidance is not applicable to WMUH
TA179	Gastrointestinal stromal tumours - sunitinib	Sep-09	No	Guidance is not applicable to WMUH
TA180	Psoriasis - ustekinumab	Sep-09	Yes	Fully implemented
TA181	Lung cancer (non-small cell, first line treatment) - pemetrexed	Sep-09	No	Guidance is not applicable to WMUH
TA182	Acute coronary syndrome - prasugrel (replaced by TA317)	Oct-09	Superseded Guidance	Superseded Guidance
TA183	Cervical cancer (recurrent) - topotecan	Oct-09	No	Guidance is not applicable to WMUH
TA184	Lung cancer (small-cell) - topotecan	Nov-09	No	Guidance is not applicable to WMUH
TA185	Soft tissue sarcoma - trabectedin	Feb-10	No	Guidance is not applicable to WMUH
TA186	Rheumatoid arthritis - certolizumab pegol (replaced by TA375)	Feb-10	Superseded Guidance	Superseded Guidance
TA187	Crohn's disease - infliximab (review) and adalimumab	May-10	Yes	Fully implemented
TA188	Human growth hormone (somatropin) for the treatment of growth failure in children (review) -	May-10	Yes	Fully implemented
TA189	Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)	May-10	No	Not recommended
TA190	Lung cancer (non-small-cell) - pemetrexed (maintenance)	Jun-10	No	Guidance is not applicable to WMUH
TA191	Gastric cancer (advanced) - capecitabine	Jul-10	No	Guidance is not applicable to WMUH

TA192	Lung cancer (non-small-cell, first line) - gefitinib	Jul-10	No	Guidance is not applicable to WMUH
TA193	Leukaemia (chronic lymphocytic, relapsed) - rituximab	Jul-10	Yes	Fully implemented
TA194	Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)	Jul-10	Terminated Appraisal	Terminated Appraisal
TA195	Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor	Aug-10	Yes	Fully implemented
TA196	Gastrointestinal stromal tumours - imatinib (adjuvant) (replaced by TA 326)	Aug-10	Superseded Guidance	Superseded Guidance
TA197	Atrial fibrillation - dronedarone	Aug-10	Yes	Fully implemented
TA198	Rheumatoid arthritis - tocilizumab (replaced by TA247)	Aug-10	Superseded Guidance	Superseded Guidance
TA199	Psoriatic arthritis - etanercept, infliximab and adalimumab	Aug-10	Yes	Fully implemented
TA200	Hepatitis C - peginterferon alfa and ribavirin	Sep-10	No	Guidance is not applicable to WMUH
TA201	Asthma (in children) - omalizumab (replaced by TA278)	Oct-10	Superseded Guidance	Superseded Guidance
TA202	Chronic lymphocytic leukaemia - ofatumumab	Oct-10	Yes	Not recommended
TA203	Liraglutide for the treatment of type 2 diabetes mellitus (replaced by NG28)	Oct-10	Superseded Guidance	Superseded Guidance
TA204	Osteoporotic fractures - denosumab	Oct-10	Yes	Fully implemented
TA205	Thrombocytopenic purpura - eltrombopag (replaced by TA293)	Oct-10	Superseded Guidance	Superseded Guidance
TA206	Lymphoma (non-Hodgkins) - Bendamustine	Oct-10	Terminated Appraisal	Terminated Appraisal
TA207	Mantle Cell Lymphoma (relapsed) - Temozolomide	Oct-10	Terminated Appraisal	Terminated Appraisal
TA208	Gastric cancer (HER2-positive metastatic) - trastuzumab	Nov-10	No	Guidance is not applicable to WMUH
TA209	Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib	Nov-10	No	Guidance is not applicable to WMUH
TA210	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (This	Dec-10	Yes	Fully implemented
TA211	Constipation (women) - prucalopride	Dec-10	Yes	Fully implemented
TA212	Colorectal cancer (metastatic) - bevacizumab	Dec-10	Yes	Not recommended
TA213	Schizophrenia - aripiprazole	Jan-11	No	Guidance is not applicable to WMUH
TA214	Breast cancer - bevacizumab (in combination with a taxane)	Feb-11	Yes	Not recommended
TA215	Renal cell carcinoma (first line metastatic) - pazopanib	Feb-11	No	Guidance is not applicable to WMUH
TA216	Leukaemia (lymphocytic) - bendamustine	Feb-11	No	Guidance is not applicable to WMUH
TA217	Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine	Mar-11	Yes	Fully implemented
TA218	Myelodysplastic syndromes - azacitidine	Mar-11	Yes	Fully implemented
TA219	Everolimus for the second-line treatment of advanced renal cell carcinoma	Apr-11	No	Guidance is not applicable to WMUH
TA220	Psoriatic arthritis - golimumab	Apr-11	Yes	Fully implemented
TA221	Thrombocytopenic purpura - romiplostim	Apr-11	Yes	Fully implemented
TA222	Ovarian cancer (relapsed) - trabectedin (replaced by TA389)	Apr-11	Superseded Guidance	Superseded Guidance
TA223	Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate	May-11	No	Guidance is not applicable to WMUH
TA224	Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal)	Jun-11	Terminated Appraisal	Terminated Appraisal
TA225	Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab	Jun-11	Yes	Fully implemented
TA226	Lymphoma (follicular non-Hodgkin's) - rituximab	Jun-11	Yes	Fully implemented
TA227	Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)	Jun-11	No	Not recommended
TA228	Multiple myeloma (first line) - bortezomib and thalidomide	Jul-11	Yes	Fully implemented
TA229	Macular oedema (retinal vein occlusion) - dexamethasone	Jul-11	No	Guidance is not applicable to WMUH
TA230	Myocardial infarction (persistent ST-segment elevation) - bivalirudin	Jul-11	No	Guidance is not applicable to WMUH
TA231	Depression - agomelatine (terminated appraisal)	Jul-11	Terminated Appraisal	Terminated Appraisal
TA232	Epilepsy (partial) - retigabine (adjuvant)	Jul-11	Yes	Fully implemented
TA233	Ankylosing spondylitis - golimumab (replaced by TA383)	Aug-11	Superseded Guidance	Superseded Guidance
TA234	Rheumatoid arthritis - abatacept (replaced by TA280)	Aug-11	Superseded Guidance	Superseded Guidance
TA235	Osteosarcoma - mifamurtide/ Mifamurtide for the treatment of osteosarcoma	Oct-11	No	Guidance is not applicable to WMUH
TA236	Acute coronary syndromes - ticagrelor	Oct-11	Yes	Fully implemented
TA237	Macular oedema (diabetic) - ranibizumab (replaced by TA274)	Nov-11	Superseded Guidance	Superseded Guidance
TA238	Arthritis (juvenile idiopathic, systemic) - tocilizumab	Dec-11	Yes	Fully implemented
TA239	Breast cancer (metastatic) - fulvestrant	Dec-11	Yes	Not recommended
TA240	Colorectal cancer (metastatic) - panitumumab	Dec-11	Terminated Appraisal	Terminated Appraisal
TA241	Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib	Jan-12	Yes	Fully implemented
TA242	Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-	Jan-12	No	Not recommended
TA243	Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of TA110)	Jan-12	Yes	Fully implemented
TA244	Roflumilast for the management of severe chronic obstructive pulmonary disease	Jan-12	No	Guidance is not applicable to WMUH
TA245	Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults	Jan-12	Yes	Fully implemented
TA246	Venom anaphylaxis - immunotherapy pharmlagen	Feb-12	No	Guidance is not applicable to WMUH
TA247	Rheumatoid arthritis - tocilizumab	Feb-12	Yes	Fully implemented
TA248	Diabetes (type 2) - exenatide (prolonged release) (replaced by NG28)	Feb-12	Superseded Guidance	Superseded Guidance
TA249	Atrial fibrillation - dabigatran etexilate	Mar-12	Yes	Fully implemented
TA250	Breast Cancer (advanced) - eribulin	Apr-12	Yes	Not recommended
TA251	Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard dose imatinib	Apr-12	Yes	Fully implemented
TA252	Hepatitis C (genotype 1) - teleprevir	Apr-12	No	Guidance is not applicable to WMUH
TA253	Hepatitis C (genotype 1) - boceprevir	Apr-12	No	Guidance is not applicable to WMUH
TA254	Multiple sclerosis (relapsing-remitting) - fingolimod	Apr-12	No	Guidance is not applicable to WMUH
TA255	Prostate cancer - cabazitaxel (replaced by TA391)	May-12	Superseded Guidance	Superseded Guidance
TA256	Atrial fibrillation (stroke prevention) - rivaroxaban	May-12	Yes	Fully implemented
TA257	Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)	Jun-12	Yes	Not recommended
TA258	Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)	Jun-12	No	Guidance is not applicable to WMUH
TA259	Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy)	Jun-12	No	Guidance is not applicable to WMUH
TA260	Migraine (chronic) - botulinum toxin type A	Jun-12	No	Guidance is not applicable to WMUH
TA261	Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban	Jul-12	Yes	Fully implemented
TA262	Ulcerative colitis (moderate to severe, second line) - adalimumab (replaced by TA329)	Jul-12	Superseded Guidance	Superseded Guidance
TA263	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	Aug-12	Yes	Not recommended
TA264	Stroke (acute, ischaemic) - alteplase	Sep-12	No	Guidance is not applicable to WMUH
TA265	Bone metastases from solid tumours - denosumab	Oct-12	Yes	Fully implemented
TA266	Cystic fibrosis - mannitol dry powder for inhalation	Nov-12	No	Guidance is not applicable to WMUH
TA267	Chronic heart failure - ivabradine	Nov-12	Yes	Fully implemented
TA268	Melanoma (stage III or IV) - ipilimumab	Dec-12	No	Guidance is not applicable to WMUH
TA269	Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib	Dec-12	No	Guidance is not applicable to WMUH
TA270	Leukaemia (acute myeloid) - decitabine (terminated appraisal)	Dec-12	Terminated Appraisal	Terminated Appraisal
TA271	Diabetic macular oedema - fluocinolone acetonide intravitreal implant (replaced by TA301)	Jan-13	Superseded Guidance	Superseded Guidance
TA272	Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine	Jan-13	No	Not recommended
TA273	Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)	Jan-13	Terminated Appraisal	Terminated Appraisal
TA274	Macular oedema (diabetic) - ranibizumab	Feb-13	No	Guidance is not applicable to WMUH
TA275	Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban	Feb-13	Yes	Fully implemented
TA276	Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin	Mar-13	No	Guidance is not applicable to WMUH
TA277	Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)	Mar-13	Terminated Appraisal	Terminated Appraisal
TA278	Asthma (severe, persistent, patients aged 6+, adults) - omalizumab	Apr-13	No	Guidance is not applicable to WMUH
TA279	Vertebral fractures - vertebroplasty and kyphoplasty	Apr-13	No	Guidance is not applicable to WMUH
TA280	Rheumatoid arthritis - abatacept (2nd line) (replaced by TA375)	Apr-13	Superseded Guidance	Superseded Guidance
TA281	Gout - canakinumab (terminated appraisal)	Apr-13	Terminated Appraisal	Terminated Appraisal
TA282	Idiopathic pulmonary fibrosis - pirfenidone	Apr-13	No	Guidance is not applicable to WMUH
TA283	Macular oedema (retinal vein occlusion) - ranibizumab	May-13	No	Guidance is not applicable to WMUH
TA284	Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer	May-13	No	Not recommended

TA285	Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab	May-13	No	Not recommended
TA286	Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal)	May-13	Terminated Appraisal	Terminated Appraisal
TA287	Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban	Jun-13	Yes	Fully implemented
TA288	Type 2 diabetes - Dapagliflozin combination therapy	Jun-13	Yes	Fully implemented
TA289	Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (replaced by TA386)	Jun-13	Superseded Guidance	Superseded Guidance
TA290	Overactive bladder - mirabegron	Jun-13	Yes	Fully implemented
TA291	Gout (tophaceous, severe debilitating, chronic) - pegloticase	Jun-13	Yes	Not recommended
TA292	Bipolar disorder (children) - aripiprazole	Jul-13	No	Guidance is not applicable to WMUH
TA293	Thrombocytopenic purpura - eltrombopag	Jul-13	Yes	Fully implemented
TA294	Macular degeneration (wet age-related) - aflibercept (1st line)	Jul-13	No	Guidance is not applicable to WMUH
TA295	Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)	Aug-13	Yes	Not recommended
TA296	Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib	Sep-13	No	Not recommended
TA297	Vitreomacular traction - ocriplasmin	Oct-13	No	Guidance is not applicable to WMUH
TA298	Choroidal neovascularisation (pathological myopia) - ranibizumab	Nov-13	No	Guidance is not applicable to WMUH
TA299	Leukaemia (chronic myeloid) - bosutinib	Nov-13	Yes	Not recommended
TA300	Hepatitis C (children and young people) - peginterferon alfa and ribavirin	Nov-13	No	Guidance is not applicable to WMUH
TA301	Diabetic macular oedema - fluocinolone acetonide intravitreal implant	Nov-13	No	Guidance is not applicable to WMUH
TA302	Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)	Nov-13	Terminated Appraisal	Terminated Appraisal
TA303	Multiple sclerosis (relapsing) - teriflunomide	Jan-14	No	Guidance is not applicable to WMUH
TA304	Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44)	Feb-14	Yes	Fully implemented
TA305	Macular oedema (central retinal vein occlusion) - aflibercept solution for injection	Feb-14	No	Guidance is not applicable to WMUH
TA306	Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy	Feb-14	Yes	Fully implemented
TA307	Colorectal cancer (metastatic) - aflibercept	Mar-14	No	Not recommended
TA308	Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)	Mar-14	Yes	Fully implemented
TA309	Lung cancer (non small cell, non squamous) - pemetrexed	Apr-14	No	Not recommended
TA310	Lung cancer (non small cell, EGFR mutation positive) - afatinib	Apr-14	No	Guidance is not applicable to WMUH
TA311	Multiple myeloma - bortezomib (induction therapy)	Apr-14	Yes	Fully implemented
TA312	Alemtuzumab for Treating Relapsing Remitting Multiple Sclerosis	May-14	No	Guidance is not applicable to WMUH
TA313	Ustekinumab for Treating Active Psoriatic Arthritis (replaced by TA340)	May-14	Superseded Guidance	Superseded Guidance
TA314	Implantable Cardioverter Defibrillators and Cardiac ReSynchronisation Therapy for Arrhythmias & Heart	Jun-14	Not discussed at DTC	
TA315	Canagliflozin in combination therapy for treating Type 2 Diabetes	Jun-14	Yes	Fully implemented
TA316	Enzalutamide for metastatic hormone relapsed prostate cancer previously treated with a docetaxel containing regimen	Jul-14	No	Guidance is not applicable to WMUH
TA317	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes	Jul-14	Yes	Fully implemented
TA318	Lubiprostone for treating chronic idiopathic constipation	Jul-14	Yes	Fully implemented
TA319	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma	Jul-14	No	Guidance is not applicable to WMUH
TA320	Dimethyl fumarate for treating relapsing remitting multiple sclerosis	Aug-14	No	Guidance is not applicable to WMUH
TA321	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation -positive melanoma	Oct-14	No	Guidance is not applicable to WMUH
TA322	Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality	Sep-14	Yes	Fully implemented
TA323	Erythropoiesis – stimulating agents for treating anaemia in people with cancer	Nov-14	Yes	Guidance is not applicable to WMUH
TA324	Dual chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block	Nov-14	Not discussed at DTC	
TA325	Nalmefene for reducing alcohol consumption in people with alcohol dependence	Nov-14	No	Guidance is not applicable to WMUH
TA326	Imantinib for the adjuvant treatment of gastrointestinal stromal tumours	Nov-14	No	Guidance is not applicable to WMUH
TA327	Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/ or pulmonary embolism	Dec-14	Yes	Fully implemented
TA328	Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments	Dec-14	Terminated Appraisal	Terminated Appraisal
TA329	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy	Feb-15	Yes	Fully implemented
TA330	Sofosbuvir for treating chronic hepatitis	Feb-15	No	Guidance is not applicable to WMUH
TA331	Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C	Feb-15	No	Guidance is not applicable to WMUH
TA332	Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer	Feb-15	Terminated Appraisal	Terminated Appraisal
TA333	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment	Feb-15	No	Guidance is not applicable to WMUH
TA334	Regorafenib for metastatic colorectal cancer after treatment for metastatic disease	Feb-15	Terminated Appraisal	Terminated Appraisal
TA335	Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome	Mar-15	Yes	Fully implemented
TA336	Empagliflozin in combination therapy for treating type 2 diabetes	Mar-15	Yes	Fully implemented
TA337	Rifaximin for preventing episodes of overt hepatic encephalopathy	Mar-15	Yes	Fully implemented
TA338	Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib	Mar-15	Yes	Not recommended
TA339	Omalizumab for previously treated chronic spontaneous urticaria	Jun-15	Yes	Fully implemented
TA340	Ustekinumab for treating active psoriatic arthritis	Jun-15	Yes	Fully implemented
TA341	Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Jun-15	Yes	Fully implemented
TA342	Vedolizumab for treating moderately to severely active ulcerative colitis	Jun-15	Yes	Fully implemented
TA343	Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia	Jun-15	Yes	Fully implemented
TA344	Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia	Jun-15	Yes	Fully implemented
TA345	Naloxegol for treating opioid-induced constipation	Jul-15	Yes	Fully implemented
TA346	Aflibercept for treating diabetic macular oedema	Jul-15	No	Guidance is not applicable to WMUH
TA347	Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non -small -cell lung cancer	Jul-15	No	Guidance is not applicable to WMUH
TA348	Everolimus for preventing organ rejection in liver transplantation	Jul-15	No	Not recommended
TA349	Dexamethasone intravitreal implant for treating diabetic macular oedema	Jul-15	No	Guidance is not applicable to WMUH
TA350	Secukinumab for treating moderate to severe plaque psoriasis	Jul-15	Yes	Fully implemented
TA351	Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti -platelet therapy (terminated appraisal)	Jul-15	Terminated Appraisal	Terminated Appraisal
TA352	Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	Aug-15	Yes	Fully implemented
TA353	Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)	Aug-15	Terminated Appraisal	Terminated Appraisal
TA354	Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism	Aug-15	Yes	Fully implemented
TA355	Edoxaban for preventing stroke and systemic embolism in people with non -valvular atrial fibrillation	Sep-15	Yes	Fully implemented
TA356	Ruxolitinib for treating polycythaemia vera (terminated appraisal)	Sep-15	Terminated Appraisal	Terminated Appraisal
TA357	Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab	Oct-15	No	Guidance is not applicable to WMUH
TA358	Tolvaptan for treating autosomal dominant polycystic kidney disease	Oct-15	Yes	Fully implemented
TA359	Idelalisib for treating chronic lymphocytic leukaemia	Oct-15	Yes	Fully implemented
TA360	Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer	Oct-15	No	Not recommended
TA361	Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)	Oct-15	Terminated Appraisal	Terminated Appraisal

TA362	Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer	Oct-15	Terminated Appraisal	Terminated Appraisal
TA363	Ledipasvir-sofosbuvir for treating chronic hepatitis C	Nov-15	No	Guidance is not applicable to WMUH
TA364	Daclatasvir for treating chronic hepatitis C	Nov-15	No	Guidance is not applicable to WMUH
TA365	Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C	Nov-15	No	Guidance is not applicable to WMUH
TA366	Pembrolizumab for advanced melanoma not previously treated with ipilimumab	Nov-15	No	Guidance is not applicable to WMUH
TA367	Vortioxetine for treating major depressive episodes	Nov-15	No	Guidance is not applicable to WMUH
TA368	Apremilast for treating moderate to severe plaque psoriasis	Nov-15	Yes	Not recommended
TA369	Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears	Dec-15	No	Guidance is not applicable to WMUH
TA370	Bortezomib for previously untreated mantle cell lymphoma	Dec-15	Yes	Fully implemented
TA371	Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane	Dec-15	No	Not recommended
TA372	Apremilast for treating active psoriatic arthritis	Dec-15	Yes	Not recommended
TA373	Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	Dec-15	Yes	Fully implemented
TA374	Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy	Dec-15	No	Guidance is not applicable to WMUH
TA375	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Jan-16	Yes	Fully implemented
TA376	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	Jan-16	No	Guidance is not applicable to WMUH
TA377	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Jan-16	No	Guidance is not applicable to WMUH
TA378	Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy	Jan-16	No	Not recommended
TA379	Nintedanib for treating idiopathic pulmonary fibrosis	Jan-16	No	Guidance is not applicable to WMUH
TA380	Panobinostat for treating multiple myeloma after at least 2 previous treatments	Jan-16	Yes	Fully implemented
TA381	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	Jan-16	No	Guidance is not applicable to WMUH
TA382	Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy	Jan-16	Terminated Appraisal	Terminated Appraisal
TA383	TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis	Feb-16	Yes	Fully implemented
TA384	Nivolumab for treating advanced (unresectable or metastatic) melanoma	Feb-16	No	Guidance is not applicable to WMUH
TA385	Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia	Feb-16	Yes	Fully implemented
TA386	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis	Mar-16	Yes	Fully implemented